NCT02004548已完成1 期
A Phase I, Multiple Dose Escalation Clinical Trial of Metatinib Tromethamine Tablet in Patients With Advanced or Metastatic Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Dose-limiting Toxicity (DLT)
研究概览
简要总结
Primary Objective: To evaluate the safety, tolerability and maximum tolerated dose (MTD) of daily oral administration of metatinib tromethamine in subjects with solid tumors; Investigate the influence of food on pharmacokinetic parameters.
Secondary Objective: To evaluate the plasma pharmacokinetics (PK) of daily oral administration of metatinib tromethamine in subjects with solid tumors; To observe preliminary anti-tumor efficacy; To evaluate potential pharmacodynamic and predictive biomarkers at MTD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Weight: male weight ≥ 45 kg; female weight ≥ 40 kg, body mass index (BMI) between 18~24 kg/m^2, including the boundary values;
- •The subject has a histologically confirmed solid tumor that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective, and there are no known therapies to prolong survival;
- •Not treated with standard therapeutical regime currently, or has progressed or relapsed after standard treatment;
- •Time from last cytotoxic chemotherapy (including investigational cytotoxic agents) or biologic agents (immune modulators, cytokines) ≥ 4 weeks, or nitrosoureas or mitomycin C ≥ 6 weeks. If having received an antibody anti-tumor biological product, at least 8-week washout period is required;
- •At least 4 weeks after surgery, and the wound must be healed completely;
- •If subject has chemotherapy-induced toxicity, the adverse events must be recovered to ≤ grade 1 (NCI-CTC version 4.0) except for alopecia;
- •ECOG performance status of 0-2;
- •Expected survival time is more than three months;
- •The subject has organ and marrow function as follows:
- •absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L,
- •platelets ≥ 80 x 10^9/L,
- •hemoglobin ≥ 90 g/L (blood transfusion is allowed),
- •total bilirubin ≤ 2 x ULN (<3 x ULN with liver metastases),
- •serum creatinine ≤ 150 μmol/L or calculated creatinine clearance ≥ 60 mL/min,
- •alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN (<5 x ULN with liver metastases),
- •uric acid <500 μmol/L,
- •proteinuria ≤ 2 + or ≤ 2g / 24h;
- •The subject is capable of understanding and complying with the protocol and has signed the informed consent document;
排除标准
- •The subject is known to be positive for the human immunodeficiency virus (HIV);
- •The subject is known to be positive for hepatitis B surface antigen or hepatitis C;
- •Previous participation in other clinical trials within three months before study;
- •Concomitant chemotherapy, hormone therapy, immunotherapy program or radiotherapy;
- •The subject has an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia;
- •The subject has psychiatric illness/social situations that would limit compliance with study requirements;
- •The subject has brain metastases;
- •Imaging study showed involvement of major blood vessels or nerves by tumor;
- •Uncontrollable hypertension (referring to systolic blood pressure> 150 mmHg and / or diastolic blood pressure> 100 mmHg after treatment) or LVEF <50%;
- •Patient with disease history of bleeding or thromboembolic events occurred within the past six months and need for preventive anticoagulant therapy;
- •Patient needs surgery within 28 days, or is expected to require surgery within 28 days after the last dose administration;
- •Significant abnormality in the important organs, such as heart, lung, liver, kidney;
- •Has third lacunar effusion with difficulty to control;
- •The subject is pregnant or breastfeeding;
- •Sexually active subjects (male and female) refuse to use medically acceptable methods of contraception during the course of the study and for 1 month following discontinuation of study drug.
研究组 & 干预措施
Metatinib Tromethamine
Experimental
Dose escalation is in accordance with the traditional "3 +3" design, and dose groups are subsequently set as: 25, 50, 100, 200, 300, 450, 600, 800 mg/d.
干预措施: Metatinib Tromethamine (Drug)
结局指标
主要结局
Dose-limiting Toxicity (DLT)
时间窗: up to day 32
Maximum Tolerated Dose (MTD)
时间窗: up to day 32
次要结局
- Cmax(d1、d2、d3、d8、d15、d22、d29、d30、d31)
- AUC(d1、d2、d3、d8、d15、d22、d29、d30、d31)
- Objective response rate (ORR)(week 4, week 10, week 16)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate CancerProstate NeoplasmsNCT01228760Astellas Pharma Inc46
招募中
1 期
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)Hemophilia AHealthy ParticipantsHemophilia AHemophilia BHemophilia BNCT06349473Equilibra Bioscience LLC31
已完成
1 期
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomasNCT01512758Millennium Pharmaceuticals, Inc.36
已完成
1 期
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid TumorsSolid TumorMicrosatellite InstabilityMismatch Repair DeficiencyCancer of Unknown Primary SiteNCT03053466Apollomics (Australia) Pty. Ltd.30
已完成
1 期
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT00794781Eisai Inc.55